The DOJ-FDA Strike Force

What the New Enforcement Model Means for Physicians, Clinics, and Regulated Businesses

The Department of Justice has quietly—but decisively—changed how it enforces FDA-regulated conduct. What was once episodic and largely administrative has evolved into something far more consequential: a permanent, prosecutor-driven enforcement model that treats FDA matters as criminal cases from the outset.

In recent months, the DOJ has formalized a structure that embeds the FDA’s Office of Criminal Investigations (FDA-OCI) directly into prosecutorial teams. While officials have not rolled out a single public-facing name, the reality is unmistakable—a de facto DOJ–FDA criminal strike force designed to accelerate prosecutions under the Federal Food, Drug, and Cosmetic Act (FDCA).

For physicians, healthcare providers, manufacturers, and executives operating in FDA-regulated environments, this shift materially changes the risk landscape.

 

A Structural Shift—Not a Temporary Initiative

Historically, FDA criminal cases were the exception, not the rule. FDA-OCI would investigate egregious misconduct—typically involving clear patient harm—and only then refer matters for prosecution. Most disputes lived and died in the administrative or civil realm.

That paradigm has changed.

Under the new model, DOJ leadership has made clear that criminal enforcement is no longer a last resort. Instead, it is a frontline tool for addressing perceived public health risks—even where the underlying conduct involves regulatory interpretation, compliance disagreements, or professional judgment calls.

In practical terms, FDA-OCI agents are now:

• Embedded at the earliest stages of investigations
  
• Coordinating directly with prosecutors from day one
  
• Building cases with criminal charges in mind, not regulatory resolution

This approach mirrors the DOJ’s strategy in healthcare fraud, national security, and financial enforcement—areas where early prosecutorial involvement has dramatically increased criminal exposure for regulated professionals.

 

Who Is at the Table of The DOJ-FDA Strike Force

A typical strike-force investigation may involve:

• FDA-OCI agents—armed federal law enforcement officers with arrest authority
  
• Assistant United States Attorneys, often from healthcare fraud, consumer protection, or white-collar units
  
• DOJ Consumer Protection Branch prosecutors specializing in FDCA enforcement
  
• Coordination with HHS-OIG, and in some cases, the FBI

What distinguishes this model is not collaboration alone, but its institutionalization. Matters that once unfolded through inspections, warning letters, and corrective action plans are now evaluated through a criminal lens from the outset.

 

The Legal Framework Being Used

The statutes most frequently deployed by DOJ–FDA strike-force teams include:

• 21 U.S.C. § 331  FDCA “prohibited acts”
• 21 U.S.C. § 351  adulterated drugs and devices
• 21 U.S.C. § 352  misbranded drugs and devices
• 18 U.S.C. § 1347  healthcare fraud (in clinical cases)

These provisions are extraordinarily broad. In many cases, prosecutors need not prove patient harm, intent to defraud, or actual injury. Alleged deviations in labeling, storage, handling, or regulatory expectations can be enough to trigger criminal exposure.

That breadth is precisely what makes the strike-force model both powerful—and dangerous.

 

Why This Matters Now

The DOJ–FDA strike force reflects a shift from outcome-based enforcement to risk-based criminalization.

Under this approach:

• Hypothetical harm can substitute for actual injury
• Regulatory disagreements can be reframed as crimes
• Industry-standard practices may be second-guessed after the fact
• Informal guidance can be weaponized through charging decisions

For physicians and clinic owners, the implications are profound. Medical judgment, sterilization protocols, device handling, and documentation practices—once assessed by regulators and licensing boards—are increasingly being evaluated by criminal investigators and juries.

 

FDA-OCI’s Evolving Role: From Inspector to Prosecutor’s Partner

FDA-OCI has long existed, but its role has fundamentally changed. Agents are no longer supporting actors in occasional prosecutions; they are now core partners in building criminal cases.

That shift carries serious consequences:

• Interviews are conducted with charging strategy in mind
• Evidence collection prioritizes prosecution, not compliance correction
• Discovery obligations and evidence-preservation issues become critical early
• Initial missteps can irreversibly damage a defense

The line between an “inspection” and a criminal investigation has blurred—and for many targets, disappeared altogether.

 

What This Means for Regulated Professionals

For anyone operating in FDA-regulated industries, the message is clear: criminal exposure now arises earlier than ever before.

Situations that warrant immediate legal counsel include:

• Repeated or escalated FDA inspections
• Requests for interviews by FDA-OCI agents
• Seizures of devices, records, or electronic data
• Coordination between FDA personnel and DOJ prosecutors
• Receipt of subpoenas, target letters, or preservation notices

Waiting for a matter to “stay administrative” is no longer a strategy—it is a gamble.

At Chapman, Dowling & Mallek, we routinely advise clients at the earliest stages of FDA and DOJ inquiries, where strategic intervention can mean the difference between regulatory resolution and criminal indictment.

 

Part of a Broader Federal Enforcement Trend

The FDA strike-force model is not an outlier. It reflects a broader DOJ philosophy: using aggressive criminal enforcement to shape regulatory compliance. Similar approaches have emerged in environmental law, financial regulation, and healthcare fraud.

Critics warn of overcriminalization and the erosion of traditional regulatory safeguards. Proponents argue that the approach deters misconduct and protects public health.

What is no longer debatable is that the terrain has shifted.

 

Final Observation

The DOJ–FDA strike force signals that FDA-regulated conduct is no longer a niche enforcement area. It is now a core component of federal criminal strategy.

For physicians, manufacturers, executives, and compliance professionals, recognizing this shift—and responding early—is essential. The question is no longer whether FDA matters can become criminal cases. It is how quickly they do—and whether those targeted recognize the change in time to protect themselves.

 

 

FDA Charges Guides

• FDA Criminal Defense FAQ
• Defending FDA Criminal Cases
• The DOJ-FDA Strike Force
• FDA Adulteration and Misbranding Charges